Fate Therapeutics competitors

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures and head of corporate development for Amgen Inc. Mr. Hagan has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts totaling over $15 billion in value. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. Mr. Hagan currently serves on the board of directors of Zosano Pharma, a publicly traded biotechnology company. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego.

Michael S. Weiss has served as the Company’s Executive Chairman, President and CEO since December 2011. Mr. Weiss is also currently a director of the Company. Mr. Weiss is a co-founder of, and has been a Managing Partner and Principal of Opus Point Partners since 2008. Mr. Weiss has also been the Executive Chairman, Strategic Development of Fortress Biotechnology since January 2014 and has served as Co-Vice Chairman of the Fortress Biotech Board of Directors since December 2013. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore. In 1999, Mr. Weiss founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as CEO of Keryx and grew the company to close to a $1BB market capitalization company at its peak. While at Keryx, he raised over $150MM in equity capital through public and private offerings, executed a $100MM+ strategic alliance, negotiated multiple Special Protocol Assessments (“SPA”) agreements with the FDA and managed multiple large clinical trials.

Serial Entrepreneur experienced in high tech start ups. Twenty years of extensive knowledge in managing complex technologies and technology product development. A proven track record of conceiving and growing companies from concept to successful market entry, developing new product concepts, sourcing and managing co-development activities both in US and in China. Demonstrated success in building and leading multi-functional teams, strategic planning, and decision making. Also an inventor with 25 issued US patents and experience in developing and managing Intellectual Property. Specialties: Conceiving and developing high tech business from concept to commercial success. Team building in high tech start up companies. Integrated product development and commercialization.

Kristi Jones is a Chief Operating Officer at NexImmune Inc and is based in San Francisco Bay Area. She has worked as Chief Business Officer at NexImmune Inc; VP:Portfolio Strategy & Management at AstraZeneca Pharmaceuticals Co Ltd; and Vice President, Global Strategic Marketing and Payer Evidence at Medimmune. Kristi works or has worked as Head:Immunology & Ophthalmology at Christof Wiesner and Vice President, Head of Portfolio Strategy and Management at Medimmune. She studied at The University of Texas at Austin and Texas Tech University Health Sciences Center.

David is an entrepreneur and angel investor who has held operating roles at six startups and invested in 70 companies. He was most recently the Chief Executive Officer of Gradifi, which was acquired by E*TRADE. Previously, he was Entrepreneur-in-Residence at Harvard Business School and Director of the Babson Summer Venture Program.For more info, see www.davidchang.mePAST EXPERIENCEDavid has a successful track record in hands-on roles at both direct-to-consumer and enterprise companies, six of which were acquired or IPO’d. He previously led the PayPal Boston office and co-founded the Start Tank innovation space and the Where Angel Fund. Before WHERE’s acquisition by PayPal in April 2011, he held the role of VP of Product, which included strategy and corporate development.Earlier in his career, on the consumer side, David was Director of New Products at TripAdvisor where he launched new features to meet consumers’ needs. He was VP of Marketing and Co-founder of SnapMyLife where he led product and marketing efforts. On the enterprise side, David was Director of Product Marketing at m-Qube, a pioneer in the mobile content space. He was Senior Product Manager at edocs and was a VP of Technology at Goldman Sachs.As a leader in the entrepreneurship community, David holds several advisor/board memberships. He is on the board at MITX, an advisor at Harvard Ventures, Nanigans, CO Everywhere, OpenFrame, and Linkwell Health. He has made 70 angel investments in startups such as Crashlytics, clypd, Amino, Logz, Cuseum, CarePort Health, Dashfire, Mogul, Uncharted Play, through the Where Angel Fund and TBD Angels. David is a frequent speaker on the topics of startups, fundraising, and the Boston tech ecosystem, and he actively mentors students and founders. Awards include Boston Business Journal's Power 50: Most Influential Bostonians, BostInno’s 50 on Fire: Education Winner / Investment Winner / Tech Finalist, and Finalist for NEVY Angel of the Year.ADVISOR ROLESBoard Member at MITX, FeelterAdvisory Board Member at Inrupt, Harvard Ventures, Nanigans, CO Everywhere, Campseekers, SharalikeAdvisor & Mentor at MassChallengeMentor at TechStarsANGEL INVESTMENTS70 angel investments in startups such as Crashlytics, clypd, Amino, CarePort Health, WEVO, Cuseum, Dashfire, Mogul, Uncharted Play, xPeerient, and through the Where Angel Fund

Cynthia Bamdad is a CEO at Minerva Biotechnologies and is based in Boston, Massachusetts. She has worked as Director at Pharmacyclics and CSO Clinical Micro Sensors, now Genmark at Minerva Biotechnologies. Cynthia works or has worked as BOARD MEMBER at Schl of Social Science, BOARD MEMBER at Urban Affairs and Public Policy, and BOARD MEMBER at Northeastern University. She attended Harvard University between 1992 and 1997 and Northeastern University.